Zenocutuzumab Extends Benefit in NRG1+ NSCLC
LEXINGTON, Mass., February 20, 2026 — New findings from a post hoc analysis of the ongoing eNRGy trial reveal...
Alzheimer’s Disease Animal Health Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cell Therapy cGxP cGxP compliance Clinical-Stage Biotech Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation oncology pipeline Orphan Drug orphan drug designation patient access Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine Regulatory Affairs regulatory approval regulatory compliance venture capital
LEXINGTON, Mass., February 20, 2026 — New findings from a post hoc analysis of the ongoing eNRGy trial reveal...
